Publications by authors named "G Kaubrys"
Immune reconstitution therapy (IRT) is a relatively new and highly effective treatment option for multiple sclerosis (MS). Uncertainty regarding the development of autoimmune disorders (ADs) after some therapies remains. The aim of this study was to assess new AD development after IRT in MS patients and to describe the nature of those ADs and the time to onset.
View Article and Find Full Text PDFDetection of neuronal antibodies for autoimmune encephalitis and paraneoplastic neurological syndromes relies on commercially available cell-based assays and lineblots. However, lineblots may reveal the presence of neuronal antibodies in patients with various non-autoimmune etiologies. Herein we describe patients with non-autoimmune etiologies (cohort B) and detectable neuronal antibodies and compare them to definite cases of autoimmune encephalitis (cohort A) for differences in clinical data.
View Article and Find Full Text PDFBackground: Approximately half of patients with multiple sclerosis (PWMS) experience sleep disorders or changes in the circadian rhythm, that may further promote the pathogenesis of multiple sclerosis. As the prevalence of chronotypes among PWMS remains unclear, we aimed to evaluate the prevalence of chronotypes among Lithuanian PWMS; to assess the relationship of chronotypes with depression, anxiety, and fatigue symptoms; and to compare these results with those of healthy controls.
Methods: We enrolled 101 PWMS and 100 healthy controls.
Article Synopsis
- The study focused on analyzing Lyme neuroborreliosis (LNB) in hospitalized adults in eastern Lithuania from 2010 to 2021, including 103 patients (100 with early LNB, 3 with late LNB).
- Early LNB frequently presented as polyradiculitis (75% of patients), with peripheral facial palsy occurring in 53% of cases, while 14% developed encephalitis or myelitis.
- A significant portion (73.8%) of patients left the hospital with lingering symptoms, and predictors for various syndromes included factors like the absence of erythema migrans (EM) and the presence of fever or pleocytosis.
Objective: To assess the differences of treatment outcomes regarding disease activity in patients with highly active relapsing multiple sclerosis (RMS), treated with autologous hematopoietic stem cell transplantation (HSCT) or alemtuzumab (ATZ).
Methods: Open-label prospective single-center observational cohort study, enrolling patients with highly active RMS for treatment with ATZ or HSCT between 2014 and 2021.
Results: A total of 50 patients (31/50 (62 %) in HSCT vs 19/50 (38 %) in ATZ group) were included.